Clinical Trial: Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Primary Immune Thrombocytopenia (ITP)
Study Type: INTERVENTIONAL
Official Title: A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)
Brief Summary:
The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ?30 G/L in adult participants with primary ITP.
Read more